-
Zhejiang Dian Diagnostics Partners with Henan Institute to Open Neuroimmunity Research Center
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a medical diagnostics company based in China, has entered into a collaboration with the Henan Institute of Medical and Pharmaceutical Sciences to establish the Engineering Technology Research Center for Accurate Diagnosis and Treatment of Neuroimmunity. The new research institute has been officially inaugurated…
-
CanSino Biologics Receives NMPA Approval for Haemophilus influenzae type B (Hib) Conjugate Vaccine Clinical Trial
•
China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its freeze-dried Haemophilus influenzae type B (Hib) conjugate vaccine. Haemophilus influenzae, a Gram-negative bacterium, is a leading cause of acute lower respiratory tract infections in children.…
-
CANbridge Pharmaceuticals’ CAN008 Fails to Meet Phase II Endpoints in Glioblastoma Multiforme
•
CANbridge Pharmaceuticals (HKG: 1228) has announced that its Phase II clinical study for CAN008 (asunercept) in newly diagnosed glioblastoma multiforme (GBM) did not achieve progression-free survival (PFS) or overall survival (OS) benefits. As a result, the Sino-US biopharma company has decided to discontinue the development of CAN008 for GBM. The…
-
Shenzhen Wingor Biotechnology Partners with Guangzhou Institute of Respiratory Health for MSC Exos Research
•
Shenzhen Wingor Biotechnology Co., Ltd, a Chinese biotechnology company, has entered into a scientific research cooperation agreement with the Guangzhou Institute of Respiratory Health (GIRH). The partnership aims to collaborate on clinical studies focusing on the use of exosomes derived from mesenchymal stem cells (MSC exos) for the treatment of…
-
Kingmed Diagnostics Partners with GenStar Biosolutions to Develop Auto-Antibody Immunofluorescence AI Software
•
Kingmed Diagnostics, a leading independent medical laboratory based in Guangdong, has entered into a strategic partnership with GenStar Biosolutions Co., Ltd, a Beijing-headquartered specialist in immune diagnostic technology. The collaboration aims to jointly develop auto-antibody immunofluorescence AI interpretation software and create an integrated, intelligent immunofluorescence detection platform. Financial details of…
-
GenScript’s Subsidiary Legend Biotech Expands EU Approval for CAR-T Therapy Carvykti
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), has secured an expanded indication approval from the European Union for its BCMA-targeted chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel). The therapy is now approved as a…
-
Ipsen’s Somatuline Receives First Prescription in China for GEP-NETs Treatment
•
French biopharmaceutical company Ipsen (EPA: IPN; OTCMKTS: IPSEY) has announced that the first prescription of its Somatuline (lanreotide) sustained-release injection has been issued in China for the treatment of gastrointestinal pancreatic neuroendocrine tumors (GEP-NETs). Somatuline, the only somatostatin analogue (SSA) for deep subcutaneous self-injection, received approval in China in December…
-
Chongqing Zhifei Biological Reports 38.3% YOY Revenue Growth in 2023 Financial Results
•
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a biopharmaceutical company based in China, has released its financial report for 2023, recording revenues of RMB 52.918 billion (USD 7.3 billion), an increase of 38.3% year-on-year (YOY). Net profits for the company were reported at RMB 8.07 billion (USD 1.11 billion), marking…
